MV Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

MV Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$54	Sell	3 -17	-85%	-$322	﹤0.01%	1258
2026 Q1	$436	Sell	20 -74	-79%	-$1.43K	﹤0.01%	995
2025 Q4	$2.02K	Buy	94 +12	+15%	+$253	﹤0.01%	723
2025 Q3	$1.58K	Sell	82 -5	-6%	-$89	﹤0.01%	734
2025 Q2	$1.49K	Buy	87 +75	+625%	+$3.2K	﹤0.01%	735
2025 Q1	$766	Buy	12 +6	+100%	+$632	﹤0.01%	781
2024 Q4	$730	Buy	6 +1	+20%	+$123	﹤0.01%	777
2024 Q3	$625	Sell	5 -5	-50%	-$691	﹤0.01%	787
2024 Q2	$1.58K	Buy	+10	New	+$1.28K	﹤0.01%	666

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

MV Capital Management's SRPT Position: Q2 2026 in Review

MV Capital Management reduced its Sarepta Therapeutics (SRPT) stake by 85% in Q2 2026, selling an estimated $322 and leaving 3 shares worth $54. The position accounts for ﹤0.01% of the portfolio, ranked #1258.

MV Capital Management first reported a position in SRPT in Q2 2024 and has held it in 9 quarters since. The position peaked at $2.02K in Q4 2025. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

MV Capital Management held 3 shares of Sarepta Therapeutics worth $54 as of Q2 2026.
MV Capital Management sold 17 Sarepta Therapeutics shares in Q2 2026, an estimated $322.
Sarepta Therapeutics made up ﹤0.01% of MV Capital Management's portfolio in Q2 2026, its #1258 holding.
MV Capital Management first reported a position in Sarepta Therapeutics in Q2 2024 and has held it in 9 quarters since.
MV Capital Management's Sarepta Therapeutics position peaked at $2.02K in Q4 2025.
324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on MV Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.